Adjuvant Treatment of Completely Resected Stages I-IV Uterine Leiomyosarcoma with Fixed-Dose Rate Gemcitabine and Docetaxel

This is a clinical practice guideline for the adjuvant treatment of completely resected stages I-IV uterine leiomyosarcoma. The guideline is intended to guide the safe and effective clinical use of fixed-dose rates of gemcitabine and docetaxel. Treatment outcomes are potentially curative and to improve progression-free survival, as well as overall survival.